Cyclophosphamide
Multi-Drug Resistant Nephrotic Syndrome
The Children's Hospital of Zhejiang University School of MedicineSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Multi-Drug Resistant Nephrotic Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ucar T-Cell The Children's Hospital of Zhejiang University School of Medicine | Phase 1 | CCC |
Fludarabine The Children's Hospital of Zhejiang University School of Medicine | Early Phase 1 | C |
RD06-05 CART Cell The Children's Hospital of Zhejiang University School of Medicine | Early Phase 1 | C |
qt-219cx The Children's Hospital of Zhejiang University School of Medicine | Early Phase 1 | C |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →